Modality
Multispecific
MOA
BiTE
Target
JAK1
Pathway
Sphingolipid
EoECrohn's
Development Pipeline
Preclinical
~May 2017
→ ~Aug 2018
Phase 1
~Nov 2018
→ ~Feb 2020
Phase 2
~May 2020
→ ~Aug 2021
Phase 3
Nov 2021
→ Apr 2030
Phase 3Current
NCT03969057
1,034 pts·EoE
2021-11→2030-04·Completed
1,034 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-06-032mo awayBTD· Crohn's
2030-04-194.1y awayPh3 Readout· EoE
Trial Timeline
Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
P3
Complet…
Catalysts
BTD
2026-06-03 · 2mo away
Crohn's
Ph3 Readout
2030-04-19 · 4.1y away
EoE
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03969057 | Phase 3 | EoE | Completed | 1034 | VA |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Ivorelsin | Eli Lilly | Approved | JAK1 | |
| LLY-3251 | Eli Lilly | Phase 2 | MDM2 | |
| RHH-974 | Roche | Preclinical | JAK1 | |
| Zanutinib | Bristol-Myers Squibb | Phase 2/3 | APOC3 | |
| Fixatenlimab | GSK | Phase 1/2 | JAK1 | |
| Bemarelsin | Daiichi Sankyo | Preclinical | GLP-1R | |
| DSN-7360 | Daiichi Sankyo | Approved | SGLT2 | |
| GIL-8529 | Gilead Sciences | Phase 1/2 | JAK1 | |
| BII-8315 | Biogen | NDA/BLA | CDK2 | |
| Geliglumide | Samsung Biologics | Phase 1 | Aβ |